Shots:

• Zydus to receive up front- development & commercial milestones and royalties on sales of Desidustat while CMS to get a license to develop & commercialize the therapy for CKD patients in Greater China
• The collaboration provides Zydus access to Greater China and facilitates the availability of Desidustat to the millions of CKD patients living with anemia
•  Desidustat is a novel oral HIF-PH inhibitor- currently being evaluated in two P-III studies (DREAM-ND & DREAM-D) in non-dialysis & dialysis CKD patients respectively and had met 1EPs and showed good safety profile in its P-II studies

Click here ­to­ read full press release/ article | Ref: Zydus Cadila | Image: Asian Age